• COVID-19: Endemic Disease
  • Products
    • ASSURE-100 Home Tests
    • ASSURE-100 POC Tests
    • Buy ASSURE-100 Tests
  • News & Updates
  • Contact Us
Buy Tests
  • COVID-19: Endemic Disease
  • Products
    • ASSURE-100 Home Tests
    • ASSURE-100 POC Tests
    • Buy ASSURE-100 Tests
  • News & Updates
  • Contact Us
  • BUY TESTS
Current COVID-19 Travel Restrictions Remaining in March 2025

Current COVID-19 Travel Restrictions Remaining in March 2025

by Oceanit | Mar 17, 2025 | General, International News

Current COVID-19 Travel Restrictions Remaining in March 2025 As of March 2025, the global landscape of COVID-19 travel restrictions has evolved significantly, with many countries lifting previous measures. However, certain nations continue to enforce specific entry...
COVID-19 Mortality Rates: U.S. and Global Trends in Late 2024 and Early 2025

COVID-19 Mortality Rates: U.S. and Global Trends in Late 2024 and Early 2025

by Oceanit | Jan 23, 2025 | Education, International News

COVID-19 Mortality Rates: U.S. and Global Trends in Late 2024 and Early 2025 As the COVID-19 pandemic evolves, mortality rates have become a key metric for understanding the ongoing impact of SARS-CoV-2 globally. In late 2024 and early 2025, advances in vaccination,...

Recent Posts

  • New 2025 COVID Vaccine Rules: What They Mean for Americans
  • Summer 2025 COVID Trends: What to Know & How to Stay Safe
  • CDC Updates 2025 COVID-19 Testing, Isolation & Recovery
  • WHO Pandemic Treaty Aims to Prevent Future Health Crises
  • Should You Keep Rapid Tests for Spring & Summer 2025?

Recent Comments

No comments to show.
Copyright 2025 Oceanit Foundry LLC. The ASSURE-100 Rapid COVID-19 Test has not been FDA cleared or approved, but has been authorized by FDA under an EUA. This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb- 3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
[dsm_icon_list list_alignment=”flex-end” _builder_version=”4.27.4″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” list_alignment_last_edited=”on|phone” list_alignment_phone=”center” sticky_enabled=”0″ list_alignment_tablet=”flex-end”][dsm_icon_list_child text=”Privacy Policy” use_icon=”off” url=”/privacy-policy/” _builder_version=”4.27.4″ _module_preset=”default” text_font=”Open Sans|700|||||||” text_text_color=”#e8e8e8″ text_font_size=”12px” text_text_color_last_edited=”off|desktop” global_colors_info=”{}” text_text_color__hover_enabled=”on|desktop” text_text_color__hover=”#1e73be”][/dsm_icon_list_child][/dsm_icon_list]